501121-91-1

Upstream product

• 501-53-1 benzyl chloroformate 
• 1226779-54-9 benzyl dibut-3-enylcarbamate 
• 132365-02-7 N-benzyl-N-(but-3-enyl)-but-3-en-1-amine 
• 501121-89-7 benzyl 8-oxa-4-azabicyclo[5.1.0]octane-4-carboxylate 
• 501121-88-6 benzyl 2,3,6,7-tetrahydro-1H-azepine-1-carboxylate0 
• 501121-90-0 benzyl 4-azido-5-hydroxyazepane-1-carboxylate 

Downstream Products

• 1440955-40-7 4-acetylamino-5-hydroxy-azepane-1-carboxylic acid benzyl ester 
• 1440955-42-9 benzyl 2-methyl-4,5,7,8-tetrahydrooxazolo[4,5-d]azepine-6-carboxylate 
• 1440955-41-8 4-acetylamino-5-oxo-azepane-1-carboxylic acid benzyl ester 

Relevant academic research and scientific papers

NOVEL COMPOUNDS

This invention relates to compounds of formula I their use as positive allosteric modulators of mGlu5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction such as schizophrenia or cognitive decline such as dementia or cognitive impairment. A, B, X, R1, R2, R3 have meanings given in the description.

NOVEL COMPOUNDS

This invention relates to compounds of formula I their use as positive allosteric modulators of mGlu5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction such as schizophrenia or cognitive decline such as dementia or cognitive impairment. A, B, X, R1, R2, R3 have meanings given in the description.

1,2,4 -TRIAZOLES AS ALLOSTERIC MODULATORS OF MGLU5 RECEPTOR ACTIVITY FOR THE TREATMENT OF SCHIZOPHRENIA OF DEMENTIA

This invention relates to compounds of formula (I) their use as positive allosteric modulators of mGlu5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction such as schizophrenia or cognitive decline such as dementia or cognitive impairment. A, B, X, R1, R2, R3 have meanings given in the description.

COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF

Provided herein are compounds and methods of synthesis thereof. The compounds provided herein are useful for the treatment, prevention, and/or management of various disorders, such as neurological disorders, psychiatric disorders, neuromuscular disorders, gastrointestinal disorders, lower urinary tract disorder, and cancer. Compounds provided herein modulate the activity of metabotropic glutamate receptor 5 (mGluR5) in the central nervous system or the periphery. Pharmaceutical formulations containing the compounds and their methods of use are also provided herein.

Parallel synthesis of substituted imidazoles from 1,2-aminoalcohols

Substituted imidazoles can be prepared efficiently from cyclic or acyclic 1,2-aminoalcohols via a four-step procedure involving acylation of the amine, oxidation of the alcohol, imine formation and cyclization. Examples are presented and the methodology i